Parnell Pharmaceuticals Holdings Ltd
PARN
PARN was delisted on the 30th of December, 2016.
19 hedge funds and large institutions have $4.61M invested in Parnell Pharmaceuticals Holdings Ltd in 2016 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 3 closing their positions.
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
19% more funds holding
Funds holding: 16 → 19 (+3)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
25% less capital invested
Capital invested by funds: $6.17M → $4.61M (-$1.56M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$716K |
| 2 |
ECM
Endurant Capital Management
San Mateo,
California
|
+$116K |
| 3 |
LTFS
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$64.3K |
| 4 |
AP
Atwood & Palmer
Kansas City,
Missouri
|
+$18.4K |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
+$18.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AG
Artal Group
Luxembourg
|
-$1.06M |
| 2 |
BlackRock
New York
|
-$51.4K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$26K |
| 4 |
Goldman Sachs
New York
|
-$8.06K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8K |
PARN Hedge Fund Activity: Q2 2016 in Review
19 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Parnell Pharmaceuticals Holdings Ltd (PARN) for Q2 2016, worth a combined $4.61M — down 25% from $6.17M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PARN positions and 3 closed out — a net gain of 3 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Sabby Management, opening a new position worth an estimated $716K. The largest seller was Artal Group, exiting entirely with an estimated $1.06M sold.
- 19 institutional investors held Parnell Pharmaceuticals Holdings Ltd (PARN) as of Q2 2016, up from 16 in Q1 2016.
- Funds reported $4.61M of Parnell Pharmaceuticals Holdings Ltd stock for Q2 2016, down 25% quarter-over-quarter.
- 6 funds opened new Parnell Pharmaceuticals Holdings Ltd positions in Q2 2016 and 3 closed out, a net change of +3 holders.
- The largest Parnell Pharmaceuticals Holdings Ltd buyer in Q2 2016 was Sabby Management, an estimated $716K added.
- The largest Parnell Pharmaceuticals Holdings Ltd seller in Q2 2016 was Artal Group, an estimated $1.06M sold.
Based on aggregated 13F filings for Q2 2016.